About ORLADEYO® (berotralstat) ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 ...

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinibREDWOOD CITY, Calif., ...

Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ...

Sprout Pharmaceuticals failed to include drug risk information in a promotional social media post, the FDA said in a warning ...

Gross proceeds from offering total $16.6 million.Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and ...

More migraine treatments than ever have become available in recent years, with more on the way. Discover the many options available in this comprehensive guide.

ORLADEYO ® (berotralstat) is the first and only oral therapy designed specifically to prevent attacks of hereditary ...

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, following a positive recommendation from the Zorginstituut Nederland ...

TiNivo-2 exploratory subgroup analysis following ICI combination treatments – –  AV-380 anti-GDF15 candidate receives generic ...

Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Congress scientific sessions in ...

Researchers have discovered that plant-derived phytochemicals and their gut microbiome metabolites control the effectiveness ...

Robust broad-spectrum efficacy sustained over 1-year across all symptom domains including negative symptoms – – Generally well-tolerated ...